KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for BioNTech SE (BNTX) over the last 7 years, with Q2 2025 value amounting to -$452783.8.

  • BioNTech SE's Gains from Sales and Divestitures fell 11022.8% to -$452783.8 in Q2 2025 from the same period last year, while for Jun 2025 it was -$452783.8, marking a year-over-year decrease of 11022.8%. This contributed to the annual value of $4.1 million for FY2023, which is 56790.54% up from last year.
  • BioNTech SE's Gains from Sales and Divestitures amounted to -$452783.8 in Q2 2025, which was down 11022.8% from -$215377.5 recorded in Q2 2024.
  • BioNTech SE's Gains from Sales and Divestitures' 5-year high stood at $5.3 million during Q4 2021, with a 5-year trough of -$452783.8 in Q2 2025.
  • Its 5-year average for Gains from Sales and Divestitures is $1.2 million, with a median of $403309.8 in 2022.
  • As far as peak fluctuations go, BioNTech SE's Gains from Sales and Divestitures skyrocketed by 87169.12% in 2023, and later tumbled by 16592.98% in 2024.
  • Over the past 5 years, BioNTech SE's Gains from Sales and Divestitures (Quarter) stood at $5.3 million in 2021, then plummeted by 88.37% to $612148.4 in 2022, then skyrocketed by 567.91% to $4.1 million in 2023, then crashed by 105.27% to -$215377.5 in 2024, then plummeted by 110.23% to -$452783.8 in 2025.
  • Its Gains from Sales and Divestitures stands at -$452783.8 for Q2 2025, versus -$215377.5 for Q2 2024 and $4.1 million for Q4 2023.